Zymo Research Pays it Forward With Their Commitment to Eradicate the COVID-19 Pandemic in India
PR91958
IRVINE, Calif., Sept. 28, 2021 /PRNewswire=KYODO JBN/ --
-- DNA/RNA Shield – DirectDetect(TM) reagent eliminates RNA extraction for
rapid deployment of COVID-19 tests in affected countries
Zymo Research has donated one million COVID-19 test kits that include its new
DNA/RNA Shield - DirectDetect(TM) reagent and collection devices to
Mapmygenome(TM) based in Hyderabad, India. Mapmygenome is a molecular
diagnostics company that provides personalized DNA testing, COVID-19 testing,
and genetic counseling to its customers. It offers personalized health
solutions to its customers based on genetic tests. They have provided COVID-19
testing throughout the pandemic at their state-of-the-art molecular testing,
cGLP-compliant laboratory as well as an onsite laboratory at the Rajiv Gandhi
International Airport in Hyderabad, India where they test incoming passengers
for the SARS-CoV-2 virus.
Photo -
https://mma.prnewswire.com/media/1636888/Zymo_Research_Corp_Pays_Forward.jpg
Photo -
https://mma.prnewswire.com/media/1636889/Anu_and_Minister_Photo2021_09_21_at_13_56_58__1.jpg
Logo - https://mma.prnewswire.com/media/364743/Zymo_Research_Corp_Logo.jpg
DNA/RNA Shield – DirectDetect, a reagent similar to Zymo Research's established
DNA/RNA Shield(TM), safeguards viral RNA from degradation for safe, ambient
temperature collection and transportation of samples without the need for
nucleic acid extraction. Removing the nucleic acid extraction step reduces the
time to get PCR test results. Compared to other reagents, DNA/RNA Shield -
DirectDetect does not inhibit downstream RT-PCR. The DNA/RNA Shield -
DirectDetect testing kit contains the DNA/RNA Shield - DirectDetect reagent
with swab collection devices.
"DNA/RNA Shield - DirectDetect enables countries seeing an increase in COVID-19
cases to perform COVID-19 testing without extraction; therefore, removing the
barrier of limited extraction resources. It's our way of providing humanitarian
support to people in need," said Dr. Marc Van Eden, Vice President of Business
Development at Zymo Research. "We teamed up with Mapmygenome because of their
ability to rapidly deploy and analyze RT-PCR testing."
"In India, where testing supplies and vaccinations are difficult to obtain,
testing is imperative to diagnosing the SARS-CoV-2 virus," said Anu Acharya,
Founder and CEO of Mapmygenome. She continued, "While many biotechnology and
testing suppliers have tended to concentrate on their domestic testing efforts,
we appreciate Zymo Research's global humanitarian effort to help eradicate
COVID-19."
For more information about DNA/RNA Shield - DirectDetect and Zymo Research's
donation program, visit their website(
).
About Zymo Research Corp.
Zymo Research is a privately owned company that has been serving the scientific
and diagnostics community with state-of-the-art molecular biology tools since
1994. The company's vision "The Beauty of Science is to Make Things Simple" is
reflected in all of their products, from epigenetics to DNA/RNA purification
technologies. Historically recognized as the leader in epigenetics, Zymo
Research is breaking boundaries with novel solutions for sample collection,
microbiomic measurements, diagnostic devices, and NGS technologies that are
high quality and simple to use. Follow Zymo Research on Facebook(
), LinkedIn(
), Twitter(
), and Instagram(
).
SOURCE: Zymo Research Corp.
CONTACT: Marketing Department, Zymo Research Corp.,+1 949.679.1190,
marketing@zymoresearch.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
